Background: Toxic epidermal necrolysis (TEN) is a rare life-threatening disease that mainly affects the skin and mucous membranes, resulting from a toxic delayed-type hypersensitivity (DTH) reaction (type IV reaction) to the presence of foreign antigens such as drugs. The clinical symptoms are caused by pathophysiological processes leading to massive apoptosis of keratinocytes in the dermo-epidermal junction. This results in the formation of a bulla and subsequent separation of the entire epidermis with the exposure of the dermis. The current approach in the local therapy of TEN prefers the use of biological dressings, which helps provide several critical requirements for defect healing; in particular, it helps in the acceleration of the spontaneous wound closure (re-epithelialization) of the skin defect and the reduction of the risk of development of various complications and infections, such as the risk of pathological scar maturation. This paper is a case report of the use of a lyophilized amniotic membrane (AM) for accelerating wound healing in a patient with TEN. Case Presentation: We report a case of an 8-year-old girl transferred to our center with a histologically confirmed diagnosis of TEN. Despite the application of immunosuppressive therapy consisting of corticosteroids and intravenous immunoglobulins, we have observed disease progression and exfoliation of up to 60% of the total body surface area (TBSA). In the facial area, which is cosmetically privileged, we decided to use the lyophilized amniotic membrane (Amnioderm®) to cover up approximately 2% of the TBSA. Within 2 days after the application, we observed accelerated reepithelialisation, with rapid wound closure. We have not observed any side effects nor infections during the subsequent phases of wound healing. Skin defects in non-facial areas of the body were treated with synthetic dressings. When compared to the areas covered with the lyophilized AM, the healing process was prolonged. Conclusions: To our knowledge, this is the first case study using a lyophilized amniotic membrane in the treatment of a patient with TEN. The AM application in the cosmetically-privileged area (face), proved to be very efficient in the treatment of TEN patients. The use of this allogeneic material demonstrated excellent biocompatibility and caused a unique acceleration of epithelialization and wound healing, yielding also excellent long-term results. The current study opens broad possibilities for clinical application of the used material, the improvement of current therapy of patients with TEN and better outcomes and recovery of patients.

Central European Institute of Technology Brno University of Technology Brno Czechia

Department of Burns and Plastic Surgery Faculty of Medicine University Hospital Brno Masaryk University Brno Czechia

Department of Paediatric Anaesthesiology and Intensive Care Medicine Faculty of Medicine University Hospital Brno Masaryk University Brno Czechia

National Tissue Centre Inc Ostrava Czechia

PrimeCell Bioscience Inc Prague Czechia

Zobrazit více v PubMed

Arevalo J. M., Lorente J. A. (1999). Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J. Burn Care Rehabil. 20, 406–410. 10.1097/00004630-199909000-00013 PubMed DOI

Bastuji-Garin S., Rzany B., Stern R. S., Shear N. H., Naldi L., Roujeau J. C. (1993). Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92–96. 10.1001/archderm.1993.01680220104023 PubMed DOI

Bhattacharya S., Tripathi H. N., Gupta V., Nigam B., Khanna A. (2011). Collagen sheet dressings for cutaneous lesions of toxic epidermal necrolysis. Indian J. Plast. Surg. 44, 474–477. 10.4103/0970-0358.90826 PubMed DOI PMC

Boorboor P., Vogt P. M., Bechara F. G., Alkandari Q., Aust M., Gohritz A., et al. . (2008). Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 34, 487–492. 10.1016/j.burns.2007.06.008 PubMed DOI

Castillo B., Vera N., Ortega-Loayza A. G., Seminario-Vidal L. (2018). Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. J. Am. Acad. Dermatol. 79, 764–767 e761. 10.1016/j.jaad.2018.03.032 PubMed DOI

Cecconi F., Alvarez-Bolado G., Meyer B. I., Roth K. A., Gruss P. (1998). Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94, 727–737. 10.1016/S0092-8674(00)81732-8 PubMed DOI

Chafranska L., Saunte D. M., Behrendt N., Nygaard U., Christensen R. J., Sand C., et al. . (2019). Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatr. Dermatol. 36, 342–345. 10.1111/pde.13778 PubMed DOI

Cirman T., Beltram M., Schollmayer P., Rozman P., Kreft M. E. (2014). Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia. Cell Tissue Bank 15, 177–192. 10.1007/s10561-013-9417-6 PubMed DOI

Creamer D., Walsh S. A., Dziewulski P., Exton L. S., Lee H. Y., Dart J. K. G., et al. . (2016). UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 (print summary - Full guidelines available at 10.1016/j.bjps.2016.01.034). J. Plast Reconstr. Aesthet. Surg. 69, 736–741. 10.1016/j.bjps.2016.01.034 PubMed DOI

Davidson B. L., Hunt J. L. (1981). Human cadaver homograft in toxic epidermal necrolysis. J. Burn Care Rehabil. 2, 94–96. 10.1097/00004630-198103000-00006 DOI

Dodiuk-Gad R. P., Chung W. H., Valeyrie-Allanore L., Shear N. H. (2015). Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am. J. Clin. Dermatol. 16, 475–493. 10.1007/s40257-015-0158-0 PubMed DOI

Endorf F. W., Cancio L. C., Gibran N. S. (2008). Toxic epidermal necrolysis clinical guidelines. J. Burn Care Res. 29, 706–712. 10.1097/BCR.0b013e3181848bb1 PubMed DOI

Firoz B. F., Henning J. S., Zarzabal L. A., Pollock B. H. (2012). Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J. Am. Acad. Dermatol. 67, 630–635. 10.1016/j.jaad.2011.12.014 PubMed DOI

Ganzetti G., Campanati A., Simonetti O., Giuliodori K., Giangiacomi M., Lemme G., et al. . (2015). Use of infliximab in toxic epidermal necrolysis: a still opened challenge. G. Ital. Dermatol. Venereol. 150, 467–471. PubMed

Gristina A. G. (1987). Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237, 1588–1595. 10.1126/science.3629258 PubMed DOI

Heimbach D. M., Engrav L. H., Marvin J. A., Harnar T. J., Grube B. J. (1987). Toxic epidermal necrolysis. A step forward in treatment. JAMA 257, 2171–2175. 10.1001/jama.1987.03390160057026 PubMed DOI

Heinrich M. A., Liu W., Jimenez A., Yang J., Akpek A., Liu X., et al. . (2019). 3D bioprinting: from benches to translational applications. Small 15:e1805510. 10.1002/smll.201805510 PubMed DOI PMC

Hsu D. Y., Brieva J., Silverberg N. B., Paller A. S., Silverberg J. I. (2017). Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J. Am. Acad. Dermatol. 76, 811–817 e814. 10.1016/j.jaad.2016.12.024 PubMed DOI PMC

Huang S. H., Wu S. H., Sun I. F., Lee S. S., Lai C. S., Lin S. D., et al. . (2008). AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 34, 63–66. 10.1016/j.burns.2006.12.008 PubMed DOI

Huang S. H., Yang P. S., Wu S. H., Chang K. P., Lin T. M., Lin S. D., et al. . (2010). Aquacel Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN). Burns 36, 121–126. 10.1016/j.burns.2009.02.018 PubMed DOI

Iranpour S., Mahdavi-Shahri N., Miri R., Hasanzadeh H., Bidkhori H. R., Naderi-Meshkin H., et al. . (2018). Supportive properties of basement membrane layer of human amniotic membrane enable development of tissue engineering applications. Cell Tissue Bank 19, 357–371. 10.1007/s10561-017-9680-z PubMed DOI

John T., Foulks G. N., John M. E., Cheng K., Hu D. (2002). Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 109, 351–360. 10.1016/S0161-6420(01)00900-9 PubMed DOI

Jongkhajornpong P., Lekhanont K., Siriyotha S., Kanokrungsee S., Chuckpaiwong V. (2017). Factors contributing to long-term severe visual impairment in Stevens-Johnson syndrome and toxic epidermal necrolysis. J. Ophthalmol. 2017:2087578. 10.1155/2017/2087578 PubMed DOI PMC

Kelly J. P., Auquier A., Rzany B., Naldi L., Bastuji-Garin S., Correia O., et al. . (1995). An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J. Clin. Epidemiol. 48, 1099–1108. 10.1016/0895-4356(95)00004-N PubMed DOI

Kinoshita Y., Saeki H. (2016). A review of the pathogenesis of toxic epidermal necrolysis. J. Nippon Med. Sch. 83, 216–222. 10.1272/jnms.83.216 PubMed DOI

Koizumi N. J., Inatomi T. J., Sotozono C. J., Fullwood N. J., Quantock A. J., Kinoshita S. (2000). Growth factor mRNA and protein in preserved human amniotic membrane. Curr. Eye. Res. 20, 173–177. 10.1076/0271-3683(200003)2031-9FT173 PubMed DOI

Kubo M., Sonoda Y., Muramatsu R., Usui M. (2001). Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest. Ophthalmol. Vis. Sci. 42, 1539–1546. Available online at: https://iovs.arvojournals.org/article.aspx?articleid=2199956 PubMed

Kucan J. O. (1995). Use of Biobrane in the treatment of toxic epidermal necrolysis. J. Burn Care Rehabil. 16, 324–327; discussion 327–328. 10.1097/00004630-199505000-00020 PubMed DOI

Lansdown A. B. (2002). Silver. I: Its antibacterial properties and mechanism of action. J. Wound Care 11, 125–130. 10.12968/jowc.2002.11.4.26389 PubMed DOI

Lavrik I. N., Krammer P. H. (2012). Regulation of CD95/Fas signaling at the DISC. Cell Death Differ. 19, 36–41. 10.1038/cdd.2011.155 PubMed DOI PMC

Lipovy B., Forostyak S. (2020). Efficacy and safety of newly developed biologic material based on the amniotic membrane in acute burns management. Burns 46, 743–745. 10.1016/j.burns.2019.12.020 PubMed DOI

Lipovy B., Rihova H., Kaloudova Y., Mager R., Suchanek I. (2014). Use of Xe-Derma((R)), a novel biological cover, in a female patient with toxic epidermal necrolysis. Ann. Burns Fire Disast. 27, 136–140. PubMed PMC

Locksley R. M., Killeen N., Lenardo M.J. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501. 10.1016/S0092-8674(01)00237-9 PubMed DOI

Marvin J. A., Heimbach D. M., Engrav L. H., Harnar T. J. (1984). Improved treatment of the Stevens-Johnson syndrome. Arch. Surg. 119, 601–605. 10.1001/archsurg.1984.01390170097019 PubMed DOI

Mccarthy K. D., Donovan R. M. (2016). Management of a patient with toxic epidermal necrolysis using silicone transfer foam dressings and a secondary absorbent dressing. J. Wound Ostomy Continence Nurs. 43, 650–651. 10.1097/WON.0000000000000287 PubMed DOI

Mccullough M., Burg M., Lin E., Peng D., Garner W. (2017). Steven Johnson Syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience. Burns 43, 200–205. 10.1016/j.burns.2016.07.026 PubMed DOI

Nassif A., Moslehi H., Le Gouvello S., Bagot M., Lyonnet L., Michel L., et al. . (2004). Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol. 123, 850–855. 10.1111/j.0022-202X.2004.23439.x PubMed DOI

Papp A., Sikora S., Evans M., Song D., Kirchhof M., Miliszewski M., et al. . (2018). Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. Burns 44, 807–815. 10.1016/j.burns.2017.10.022 PubMed DOI

Paradisi A., Abeni D., Bergamo F., Ricci F., Didona D., Didona B. (2014). Etanercept therapy for toxic epidermal necrolysis. J. Am. Acad. Dermatol. 71, 278–283. 10.1016/j.jaad.2014.04.044 PubMed DOI

Rodriguez-Martin S., Martin-Merino E., Lerma V., Rodriguez-Miguel A., Gonzalez O., Gonzalez-Herrada C., et al. . (2019). Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur. J. Clin. Pharmacol. 75, 237–246. 10.1007/s00228-018-2569-3 PubMed DOI

Rogers A. D., Blackport E., Cartotto R. (2017). The use of Biobrane((R)) for wound coverage in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Burns 43, 1464–1472. 10.1016/j.burns.2017.03.016 PubMed DOI

Roujeau J. C., Stern R. S. (1994). Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272–1285. 10.1056/NEJM199411103311906 PubMed DOI

Saiag P., Caumes E., Chosidow O., Revuz J., Roujeau J. C. (1992). Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J. Am. Acad. Dermatol. 26, 567–574. 10.1016/0190-9622(92)70082-Q PubMed DOI

Schopf E., Stuhmer A., Rzany B., Victor N., Zentgraf R., Kapp J. F. (1991). Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch. Dermatol. 127, 839–842. 10.1001/archderm.1991.01680050083008 PubMed DOI

Schulz J. T., Sheridan R. L., Ryan C. M., Mackool B., Tompkins R. G. (2000). A 10-year experience with toxic epidermal necrolysis. J. Burn Care Rehabil. 21, 199–204. 10.1097/00004630-200021030-00004 PubMed DOI

Schwartz R. A., Mcdonough P. H., Lee B. W. (2013). Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J. Am. Acad. Dermatol. 69, 173 e171–113; quiz 185–176. 10.1016/j.jaad.2013.05.003 PubMed DOI

Shanbhag S. S., Rashad R., Chodosh J., Saeed H. N. (2019). Long-term effect of a treatment protocol for acute ocular involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Am. J. Ophthalmol. 208, 331–341. 10.1016/j.ajo.2019.07.006 PubMed DOI PMC

Sippel K. C., Ma J. J., Foster C. S. (2001). Amniotic membrane surgery. Curr. Opin. Ophthalmol. 12, 269–281. 10.1097/00055735-200108000-00006 PubMed DOI

Smith S. D., Dodds A., Dixit S., Cooper A. (2015). Role of nanocrystalline silver dressings in the management of toxic epidermal necrolysis (TEN) and TEN/Stevens-Johnson syndrome overlap. Aust. J. Dermatol. 56, 298–302. 10.1111/ajd.12254 PubMed DOI

Spies M., Sanford A. P., Aili Low J. F., Wolf S. E., Herndon D. N. (2001). Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 108, 1162–1168. 10.1542/peds.108.5.1162 PubMed DOI

Ventura F., Fracasso T., Leoncini A., Gentile R., De Stefano F. (2010). Death caused by toxic epidermal necrolysis (Lyell syndrome). J. For. Sci. 55, 839–841. 10.1111/j.1556-4029.2010.01338.x PubMed DOI

Yang C. W., Cho Y. T., Chen K. L., Chen Y. C., Song H. L., Chu C. Y. (2016). Long-term sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Acta Derm. Venereol. 96, 525–529. 10.2340/00015555-2295 PubMed DOI

Yang J. Y., Huang C. Y., Chuang S. S., Chen C. C. (2007). A clinical experience of treating exfoliative wounds using nanocrystalline silver-containing dressings (Acticoat). Burns 33, 793–797. 10.1016/j.burns.2006.11.010 PubMed DOI

Zhang S., Tang S., Li S., Pan Y., Ding Y. (2020). Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J. Dermatol. Treat. 31, 66–73. 10.1080/09546634.2019.1577548 PubMed DOI